MSB

2.58%

94.5¢ mesoblast limited

SMH commentary 18 June, page-3

First 3 Last

Share
Profile

Follow
hottuna

3,053 Posts.

2

18/06/16

08:52

Post #: 18062777
Share

Originally posted by benelong ↑

http://www.smh.com.au/business/true...c-mesoblast-will-succeed-20160617-gplayx.html

Sure, Waslitz = Thorney = 5.2% shareholder, but the stated reasons for Teva going are unambiguous. And while there might be some ambiguity about the placing of quote marks and whether it is Waslitz or Kolbert saying:

But as Teva shifted its focus to generic drugs, its decision to quit funding Mesoblast's heart treatment was unsurprising, he (= Waslitz) said, and now Mesoblast has little choice but to pursue the drug's development.

"I thought Teva would walk two years ago when its leadership changed," said Jason Kolbert, analyst with Maxim Group in the US.

"The fact that it didn't is testament to Silviu, Teva did not decide this on the research data [outcome]. It was credible when Silviu said the decision was a strategic move by Teva.

"The outlook for Mesoblast with its chronic heart failure treatment hasn't changed. What has changed is it has to finance it. Also it now has 100 per cent equity in the program."

(bolds, italics and parentheses are mine)

The first paragraph of the quote is Waslitz. The second is Kolbert. I hope the third is also Kolbert. That would be a huge turnaround by Kolbert from his conference call sourness.

Thorney's Waislitz argues the heart program is central to Mesoblast's future fortunes. But how to fund it?

The science is still as good as it was. Clearly, as stated by M Schuster and posited by Lodge and Thorney, Teva's departure cannot be taken as commentary on the CHF program. Can't say it more plainly.

The sp rout has been a colossal overreaction except, as warned by @madamswer and others and detailed in Lodge and Waslitz, MSB now has to fund a very expensive program. If an arrangement with a cardiac savvy partner is executed we'll be back on track and better than with Teva. We can only wait and see where the $ come from and what it will cost.

Expand

All this would be great, if it wasn't for the fact that contractually Teva couldn't walk unless the surrogate endpoints weren't met - that's black and white, no matter what an analyst and Silviu's best mate have to say.

Last edited by hottuna: 18/06/16

MSB Price at posting: $1.06 Sentiment: Sell Disclosure: Held
2 Upvote

0 Great analysis

Reply

Top Stories

PRU

Perseus Mining boosts stake in Predictive Discovery to 19.9% as latter's flagship project stalls

OCC

Orthocell kicks off collagen-based dental bone repair product sales in Canada; eyeing next stop Brazil

CBA breaks trading record on strong day for Aussie financials

BIT

HotCopper users blunt as Biotron sinks -35%; long-awaited COVID drug results same as placebo

LAM

Laramide sniffs prime Kazakh uranium, with agreement over 6000 square km land position

QML

Metallurgical testing shows saleable copper and pyrite from QMines' Develin Creek project

Week 36 Wrap: AI hype wave tested again; Oz per capita recession continues; AirTrunk’s $40B+ payday

SBW

Shekel Brainweigh investor presentation webinar – the future of retail automation

RMX

Red Mountain Mining: record gold prices, two projects, two greenstone belts

As Nvidia cools, we're looking to Aussie AI

There are more pages in this discussion • 189 more messages in this thread...

First 3 Last

Add MSB (ASX) to my watchlist

(20min delay)
Last 94.5¢		Change -0.025(2.58%)		Mkt cap ! $1.078B

Open	High	Low	Value	Volume
98.0¢	98.5¢	94.0¢	$2.482M	2.602M

Buyers (Bids)

No.	Vol.	Price($)
6	71720	94.0¢

Sellers (Offers)

Price($)	Vol.	No.
94.5¢	10463	1

View Market Depth

No.	Vol.	Price($)
6	71720	0.940
7	80257	0.935
5	107550	0.930
6	117669	0.925
6	104084	0.920

Price($)	Vol.	No.
0.945	10463	1
0.950	71797	3
0.955	114621	4
0.960	52017	4
0.965	44050	3

Last trade - 16.10pm 06/09/2024 (20 minute delay)

MSB (ASX) Chart

SMH commentary 18 June, page-3

Perseus Mining boosts stake in Predictive Discovery to 19.9% as latter's flagship project stalls

Orthocell kicks off collagen-based dental bone repair product sales in Canada; eyeing next stop Brazil

CBA breaks trading record on strong day for Aussie financials

HotCopper users blunt as Biotron sinks -35%; long-awaited COVID drug results same as placebo

Laramide sniffs prime Kazakh uranium, with agreement over 6000 square km land position

Metallurgical testing shows saleable copper and pyrite from QMines' Develin Creek project

Week 36 Wrap: AI hype wave tested again; Oz per capita recession continues; AirTrunk’s $40B+ payday

Shekel Brainweigh investor presentation webinar – the future of retail automation

Red Mountain Mining: record gold prices, two projects, two greenstone belts

As Nvidia cools, we're looking to Aussie AI

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

SMH commentary 18 June, page-3

Top Stories

Perseus Mining boosts stake in Predictive Discovery to 19.9% as latter's flagship project stalls

Orthocell kicks off collagen-based dental bone repair product sales in Canada; eyeing next stop Brazil

CBA breaks trading record on strong day for Aussie financials

HotCopper users blunt as Biotron sinks -35%; long-awaited COVID drug results same as placebo

Laramide sniffs prime Kazakh uranium, with agreement over 6000 square km land position

Metallurgical testing shows saleable copper and pyrite from QMines' Develin Creek project

Week 36 Wrap: AI hype wave tested again; Oz per capita recession continues; AirTrunk’s $40B+ payday

Shekel Brainweigh investor presentation webinar – the future of retail automation

Red Mountain Mining: record gold prices, two projects, two greenstone belts

As Nvidia cools, we're looking to Aussie AI

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News